NICE’s second Zytiga rejection ‘shows need for flexible pricing models’NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a Share XNICE’s second Zytiga rejection ‘shows need for flexible pricing models’https://pharmaphorum.com/news/nice-second-zytiga-rejection-shows-need-for-flexible-pricing-models/
